All In Biotech

Free tool

FAERS Monitor: Keytruda Qlex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761467 or its brand name (Keytruda Qlex, Pembrolizumab, Berahyaluronidase Alfa-Pmph). Reports on generic versions are filed under their own applications.

Reports

56

Serious

21

38% of reports

Hospitalization

17

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue5
  • inappropriate schedule of product administration4
  • injection site erythema4
  • therapy change4
  • arthralgia3
  • injection site pain3
  • no adverse event3
  • pain3
  • product use issue3
  • pruritus3
  • rash3
  • adrenal insufficiency2
  • asthenia2
  • autoimmune disorder2
  • cough2

Reports by year received

View as table
YearReports
20252
202654

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,103 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy changeSignal4152.859.4461
autoimmune disorder277.119.884
adrenal insufficiency261.915.967
injection site erythemaSignal412.14.731
inappropriate schedule of product administrationSignal48.33.219
no adverse eventSignal36.22.19
product use issueSignal36.02.08
injection site pain33.71.24
pruritus32.91.02
arthralgia32.70.92
cough22.70.71
rash32.60.92
fatigue52.41.03
asthenia22.00.50
pain31.80.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.